Oxaliplatine Accord (Oxaliplatin)

Oxaliplatin exerts its antitumor effect by forming covalent cross‑links between DNA bases, which disrupts DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially targeting rapidly dividing cancer cells while sparing most normal tissues.

The specific dose and schedule of Oxaliplatine Accord are determined by the prescribing oncologist based on the patient’s clinical condition, treatment protocol, and renal function. Healthcare professionals set the appropriate regimen and adjust it as needed.

The safety of oxaliplatin in pregnancy and lactation has not been established. It is generally contraindicated in pregnant women because of potential fetal toxicity, and breastfeeding is not recommended while receiving treatment due to possible drug excretion in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Oxaliplatin differs from cisplatin and carboplatin in its chemical structure and toxicity profile. It tends to cause less nephrotoxicity and ototoxicity but is more associated with peripheral neuropathy. Clinicians select oxaliplatin when a favorable renal safety profile is desired, especially in colorectal cancer regimens.

Oxaliplatine Accord should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging until use, and the solution should be inspected for particulate matter before administration.

The drug is supplied as an injectable solution for intravenous infusion. It is typically diluted in a compatible IV fluid and administered over a prescribed period, often 2 hours, under the supervision of qualified medical personnel.

Serious risks include severe hypersensitivity reactions (anaphylaxis), pulmonary toxicity (interstitial lung disease), and profound thrombocytopenia or neutropenia that can lead to life‑threatening infections or bleeding. Prompt recognition and management of these events are essential.

Patients with known hypersensitivity to oxaliplatin or other platinum compounds, those with severe renal impairment, pregnant women, and individuals with uncontrolled neuropathy should avoid Oxaliplatine Accord. Clinical judgment is required for all contraindications.